Trial Information
Phase II Study of Iressa in Relapsed and Refractory Small Cell Lung Cancer
Inclusion Criteria:
- Provision of written informed consent
- Histologically confirmed, relapsed or refractory SCLCr
- Aged 18 or over and a life expectancy of more than 2 months
Exclusion Criteria:
- Any evidence of clinically active interstitial lung disease
- Other co-existing malignancies or malignancies diagnosed within the last 5 years,
with the exception of basal cell carcinoma or cervical cancer in situ.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To determine the disease control rate in these patients
Principal Investigator
AstraZeneca Iressa Medical Science Director, MD
Investigator Role:
Study Director
Investigator Affiliation:
AstraZeneca
Authority:
Denmark: Danish Medicines Agency
Study ID:
1839IL/0559
NCT ID:
NCT00298688
Start Date:
September 2004
Completion Date:
March 2007
Related Keywords:
- Small Cell Lung Cancer
- Lung Neoplasms
- Small Cell Lung Carcinoma